No Prescription |
 |
 | ||
|
LYNORAL Estinyl |
|
| ||
No Prescription » Prescription Drugs 10 » LYNORAL Estinyl Estrogens (ES-troe-jenz) and progestins (pro-GEST-ins) are female hormones. They are produced by the body and are necessary for the normal sexual development of the female and for the regulation of the menstrual cycle during the childbearing years. Buy LYNORAL Estinyl and other Prescription Drugs 10 products online at Medstore. Buy Online at Medstore - Click Here!
About LYNORAL Estinyl: Product Type: Prescription Drugs 10 LYNORAL ( Estinyl Generic Ethinyl Estradiol ) LYNORAL (Estinyl Generic Ethinyl Estradiol) Estinyl Generic Ethinyl Estradiol 10mcg Tabs 100 (10 x 10) 10mcg Tabs 300 ( 30 x 10 ) 50mcg Tabs 300 ( 30 x 10 ) 50mcg Tabs 100 (10 x 10) 0.01mg 400 Tablets 0.01mg 200 Tablets 0.01mg 100 Tablets 50mcg 200 Tablets 50mcg 400 Tablets 50mcg 100 Tablets Estinyl Generic Ethinyl Estradiol LYNORAL
View more Prescription Drugs 10 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
